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ABSTRACT
Introduction: Curcumin is an active constituent derived from turmeric with a variety of pharmacological activities. 
It suppressed cell proliferation and induced apoptosis in several cancer cell lines. However, due to its poor bio-
availability, derivative analogue of curcumin has been synthesized to enhance the drug-like effects. BHMC was 
synthesized by removing β-diketone moiety from curcumin structure and modify it into conjugated double bonds. 
It has been proved to exhibit stronger anticancer effects with improved bioavailability compared to curcumin. Ob-
jective: This study aims to investigate the toxicity effect of BHMC and curcumin on human liver cancer, HepG2 
and non-cancer mouse fibroblast, 3T3. Methods: Both cell lines were purchased from ATCC and cultured in sup-
plemented DMEM. Cell viability was determined via MTT assay and confirmed with trypan blue assay. Morphology 
hallmarks of apoptosis of both treated cells were analyzed using inverted microscope at 40X magnifications. Results: 
BHMC and curcumin were very potent towards HepG2 and normal 3T3. These data were further confirmed with 
trypan blue assay which showed that both compounds significantly reduced the percentage of HepG2 and 3T3 cells 
viability. Both treated cells also displayed all the morphology hallmarks of apoptosis upon treatment. Conclusion: 
BHMC has a greater cytotoxicity effect on HepG2 compared to curcumin despite its non-selective cytotoxicity effect 
on non-cancer 3T3. 
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INTRODUCTION
Cancer is defined as a set of diseases characterized by 
upregulated cell growth, invasion to surrounding tissues 
and metastasis to other parts of the body. Hepatocellular 
carcinoma (HCC) is one of the most common malignant 
tumors and third leading cause of cancer death 
worldwide (2). It is reported that HCC usually associated 
with chronic liver infection with 80% of HCC is caused 
by hepatitis B virus (HBV) and hepatitis C virus (HCV), as 
well as other important risk factors such as liver cirrhosis 
from excessive alcohol consumption, genetic liver 
disease, primary hemochromatosis and also including 
exposure to dietary carcinogens especially aflatoxin (1). 
Thus, since HCC is an aggressive tumour that associated 
with poor prognosis, chemotherapy plays crucial role in 
this treatment especially in HCC patients with advance 
stages when other options of treatments like resection 
and liver transplantation are inapplicable (6). Sorafenib 
is a standard chemotherapeutic agent for patients with 
very advanced HCC. However, it only provides limited 
survival advantage with wide profile of adverse effects 
and toxic manifestations such as thrombocytopenia, 
hand foot syndrome and mucositis (3). Therefore, due to 
the limited therapeutic applications of HCC treatments 
along with the development of drug resistance, novel 
strategies were undertaken by great deal of research 
focusing more on the bioactive compound as an 
alternative for liver cancer therapy.
Many chemotherapeutic agents are phytochemicals, 
the secondary metabolites that are naturally found in 
plants with protective or preventive properties (4). This 
natural dietary and polyphenolic compounds showed 
to have various biological activities that target specific 
pathways and enzymes and effectively fight against 
carcinogenesis. Curcumin (diferuloyl-methane) is one 
of the polyphenolic compounds derived from turmeric 
(Curcuma longa). It has been shown to have wide 
variety of pharmacological activities such as antioxidant, 
antimicrobial, anti-inflammation and anticancer 
properties (16). Besides, it has also been shown to 
regulate a diverse array of cellular signaling pathways, 
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gene expression, various signaling molecules and can 
also act as inhibitor of transcription factor nuclear factor-
kappa B (NF-κB), downstream gene products, as well 
as inducible enzyme activity (26). Numerous in vitro 
studies indicated that curcumin capable to suppress 
cancer cell proliferation and promote apoptosis as well 
as cell-cycle arrest via modulating two crucial tumour 
cell survival pathways: NF-κB and protein kinase B (Akt) 
(3). Although curcumin is remarkably non-toxic and has 
promising anti-cancer activities, preclinical and clinical 
studies indicate that curcumin has one major limitation 
in which it has poor bioavailability and pharmacokinetic 
profiles (28). Previous studies have also demonstrated 
lower serum and tissue levels of curcumin irrespective 
of route of administration, rapid metabolism and 
elimination as the major factors curtailing curcumin 
bioavailability. These had been observed occurred in 
both animals and humans (11, 24) and it is due to its 
hydrophobic property in nature (14). Moreover, there 
are two major in vitro stability issues that complicate its 
use as a pharmaceutical that are oxidative degradation 
and modification and solvolysis (11). Thus, there are 
attempts to improve the solubility of hydrophobic 
curcumin and increased its bioavailability (24). 
Numerous synthetic derivative analogue of curcumin has 
been synthesized in order to improve the bioavailability of 
curcumin as well as enhancing the anti-tumour activities 
that have a safety profile similar to curcumin. 2,6-bis-
4-(hydroxyl-3-methoxy-benzylidine)-cyclohexanone 
(BHMC) is one of mono-carbonyl curcumin analogue 
synthesized based on the chemical structure of 
curcumin by removing the unstable β-diketone moiety 
and modifying into conjugated double bonds while 
preserving the hydroxyl (OH) group (23). The presence 
of β-diketone moiety causes curcumin to have low 
bioavailability since it can be rapidly metabolized by 
aldo-ketoreductase in liver which limited the potential 
therapeutic effect of curcumin on many types of diseases 
(13). The difference in the structure of BHMC allows it to 
be more selective in suppressing various inflammatory 
mediators as well as demonstrated greater effects of 
anti-ulcerogenic and anticancer activities compared 
to curcumin (23, 25). It has also been reported that 
BHMC was more potent towards breast cancer cell lines 
MDA-MB-231, MCF-7 and SKBr-3 with low toxicity 
profile in normal cells (4). In mouse 4T1 triple negative 
breast cancer (TNBC) cell model, BHMC demonstrated 
better cytotoxicity effect in vivo compared to curcumin 
via suppression of inflammation, proliferation and 
metastasis (23). Thus, this project aims to investigate the 
cytotoxicity effect of BHMC and curcumin on human 
hepatocellular carcinoma, HepG2. 
 
MATERIALS AND METHODS
Chemical and reagents
Dulbecco’s Modified Eagle Medium (DMEM) (4.5G/L 
Glucose) with L-Gln and sodium pyruvate (Nacalai), 
penicillin and streptomycin, trypsin EDTA were purchased 
from PAA Laboratories GmBH (Pasching, Austria) and 
phosphate buffered saline (PBS) (Oxoid) was purchased 
from ATOZ Scientific (Japan). Dimethylsulfoxide 
(DMSO), MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), ethanol absolute 
denatured, foetal bovine serum (FBS) were purchased 
from Sigma-Aldrich Co. (St. Louis, MO, USA). BHMC 
was 99.9% pure as determined by HPLC meanwhile 
curcumin was purchased from Sigma Chemical Co. (St. 
Louis, MO). Curcumin and BHMC were first dissolved 
in filtered 100% DMSO as stock at 50μM and 100μM, 
respectively and diluted to appropriate concentration for 
assays. The final concentration of DMSO in all assays 
was kept constant at 0.1%. 
Cell lines
Human hepatocellular carcinoma cell, HepG2 and non-
cancer mouse fibroblast cell, 3T3 were purchased from 
American Type Culture Collection (ATCC), USA.  The 
cells were cultured in complete DMEM medium and 
incubated at 37oC in a 5% CO
2
 incubator. 
Growth inhibition assay 
Cytotoxicity activity of BHMC and curcumin was 
determined using MTT assay in accordance to 
Danihelova et al. (7) with some modifications. MTT 
assay involved measuring the metabolism of (3-
(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide to form an insoluble formazan precipitate 
by mitochondria dehydrogenase which is specifically 
present in viable cells. Cells at 70-80% of confluency 
were harvested with trypsin-EDTA. Initially, 100μL of 
HepG2 and 3T3 cell suspension of 1 x 105 (cells/mL) 
was seeded in triplicate of 96-well plate. The cells were 
incubated overnight at 37oC with 5% CO
2
 and treated 
with various concentrations of BHMC and curcumin 
(0, 0.78, 1.563, 3.125, 6.25, 12.5, 25 and 50 μM). The 
treated cells were then incubated again at 37oC in a 5% 
CO
2
 humidified incubator for 24, 48 and 72 hours. After 
24 hours, 20μl of MTT solution (5mg/mL) in 1x PBS was 
added to the medium of each well and the plate was left 
for incubation at 37oC for 4 hours. The absorbance at 
570 nm and the reference wavelength of 630 nm were 
measured with a microplate reader (Opsys MR, USA).
Trypan blue exclusion assay
Trypan blue exclusion assays were perform according 
to Gevrenova et al. (8) with some modifications. HepG2 
and 3T3 (1.5x 105cells/mL) were treated with various 
concentration of curcumin (25 and 50 μM) and BHMC 
(5, 10 and 15 μM) in 6-well plates with untreated as a 
control. The cells were incubated at 37oC and 5% CO
2
 
for 24, 48 and 72 hours. After each incubation time, 
the existing medium was collected into centrifuged 
tube and trypsin-EDTA (1 mL) was added into each 
well. The plate was incubated at 37oC for 10 minutes. 
Following that, the collected medium was poured into 
the respective well. Subsequently, 10 μL of trypan blue 
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dye solution was mixed with equal volume of the cell 
suspension. The viable and dead cells were counted 
under an inverted microscope and tabulated. The test 
was performed in a laminar flow hood.  The percentage 
of the cell viability was calculated with the following 
formula:
Cell viability (%):   Total viable cells (unstained)     x 100
                           Total cells (stained n unstained)
Cell morphology 
Based on previous method by Ng et al. (22) with some 
modifications, morphological changes of treated cells 
were observed under inverted microscope. Both HepG2 
and 3T3 were treated with various concentrations of 
curcumin (25 and 50 μM) and BHMC (5, 10 and 15 
μM) in 6-well plate with untreated as a control. Cells 
were incubated at 37oC and 5% CO
2
 for 24 hours. 
Morphological changes of treated cells were viewed 
under inverted microscope.
Data analysis
All data was analyzed using the software package Prism 
GraphPad Programme (GraphPad Software). Error bars 
represent ± the standard error of the mean (S.E.M.) for 
the data set. Comparisons within groups of data were 
analyzed using one-way analysis of variance (ANOVA) 
followed by Dunnett post hoc test using Statistical 
Package for Social Science (SPSS) version 21.0. The 
probability of p < 0.05 was considered statistically 
significant.
RESULTS
Cytotoxicity effect of BHMC and curcumin on HepG2 
and 3T3 via MTT assay
Both HepG2 and 3T3  were treated with different 
concentration of BHMC and curcumin (0, 0.78, 1.563, 
3.125, 6.25, 12.5, 25 and 50 μM). Data obtained for both 
compounds following three incubation periods (24, 48 
and 72 hours) was used to calculate IC
50
 values (Table 
I). Each value is the mean ± S.E.M of three independent 
experiments. Results from this study showed that both 
compounds exhibited a concentration- and time-
dependent anti-proliferative profile in both cell lines. 
Table I shows the IC
50
 values of BHMC and curcumin 
as tested in HepG2 and 3T3 at different time incubation. 
The result indicated that both compounds exhibited 
cytotoxicity effect on both cancer and non-cancerous 
cells. Although curcumin appeared to be most toxic 
towards HepG2  after 72 hours of incubation compared 
to 24 and 48 hours, BHMC was found to be more toxic 
towards HepG2 compared to curcumin. BHMC was 
also appeared to be most potent towards 3T3 with lower 
IC
50
 value at all incubation time (IC
50
~ 3μM).
Cytotoxicity effect of BHMC and curcumin on HepG2 
and 3T3 via trypan blue assay.
To further confirm the toxicity of BHMC and curcumin 
on HepG2, trypan blue exclusion assay was performed 
to measure the viability and toxicity of cells after treated 
with various concentrations. The assay is based on the 
basic principle that viable cells do not take up blue 
dyes, while dead cells do. Only three concentrations 
(5, 10 and 15 μM) of BHMC and two concentrations 
of curcumin (25 and 50 μM) were selected based on 
the IC
50
 values obtained from MTT assay. 3T3 was 
included to measure the selective cytotoxicity of both 
compounds. Total number of viable cells were counted 
using haemocytometer where the cell suspension is 
mixed with trypan blue solution depending on the 
time incubation (24, 48 and 72 hours). Fig.1 showed 
that BHMC significantly reduced more than 40% of 
HepG2 viability (p<0.001) when treated with selected 
concentrations for 24 hours. More cell populations 
decreased gradually with increasing concentration and 
time points.  Similar toxicity effects of BHMC were also 
observed on 3T3 with over 40% of cell death (p<0.01) 
Table I: Cytotoxic effects of BHMC and curcumin on HepG2 and 3T3 
reflected by the IC
50
 values as determined by MTT assay.
Incubation 
time (hours)
IC50 ( μM)
HepG2 3T3
BHMC Curcumin BHMC Curcum-
in
24 16.85 ± 
2.49
46.13 ± 
0.254
5.50 ± 
0.211
35.32 ± 
6.27
48 4.97 ± 
1.47
26.30 ± 
2.76
3.03 ± 
0.413
17.67 ± 
1.88
72 2.73 ± 
0.759
17.93 ± 
1.97
3.05 ± 
0.446
18.37 ± 
1.87
Figure 1: Effect of BHMC on (A) HepG2 and (B) 3T3 cells viability at 
24, 48 and 72 hours. Both cells were counted by using a haemocytom-
eter and the percent cell viability was measured using the trypan blue 
exclusion method. Data are presented as mean ±S.E.M. and represent 
of two independent experiments. Statistically significant differences 
are indicated (*p<0.01; **p< 0.001).
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Figure 2: Effect of curcumin on (A) HepG2 and (B) 3T3 cells viability at 
24, 48 and 72 hours. Both cells were counted by using a haemocytom-
eter and the percent cell viability was measured using the trypan blue 
exclusion method. Data are presented as mean ±S.E.M. and represent 
of two independent experiments. Statistically significant differences 
are indicated (*p<0.01; **p< 0.001).
recorded with increasing concentrations and incubation 
periods. Meanwhile, Fig. 2 showed that both curcumin 
treated HepG2 and 3T3 cells has reduced cell viability by 
approximately 20% (p<0.001) after 24 hours treatment, 
and 30%-90% (p<0.001) after 48 and 72 hours treatment 
compared to control. Therefore, this confirms the toxicity 
effects of both BHMC and curcumin on HepG2 as well 
as non-cancer 3T3 obtained from MTT assay. 
Morphological changes of HepG2 and 3T3 upon 
treatment with BHMC
Treatment with several concentrations of BHMC showed 
significant morphological changes in both HepG2 and 
3T3 compared to control after 24 hours incubation. At 
higher concentrations, more cells underwent membrane 
blebbing followed by apoptotic bodies. Cells population 
decreased with increasing concentration of BHMC. 
Similarly, 3T3 also demonstrated morphological 
changes upon treated with three different concentrations 
of BHMC (Fig. 3). Cells morphology was observed using 
an inverted microscope. 
Morphological changes of HepG2 and 3T3 upon 
treatment with curcumin
Treatment with 25μM of curcumin showed significant 
morphological changes in both HepG2 and 3T3 
compared to control after 24 hours incubation (Fig. 4). 
At higher concentration of 50μM, membrane blebbing 
started to form with some cells forming apoptotic 
bodies. Similarly, 3T3 also demonstrated morphological 
Figure 3: Morphological changes of BHMC-treated HepG2 and 3T3 
observed under an inverted light microscope (40X magnifications). 
Cell population decreased with the increase in the compound con-
centration. Both treated cells showed the apoptotic features such as 
cellular detached cell (dc), cell shrinkage (cs) and membrane blebbing 
(mb) and formation of apoptotic bodies (ab). Healthy cells remained 
attached (ac) to the surface of the flask.
changes upon treated with both 25 and 50 μM of 
curcumin. DMSO was included as negative control. 
Cells morphology was observed using an inverted 
microscope. 
DISCUSSION
Curcumin is a bioactive compound derived from Curcu-
ma longa and has been acknowledged to have potential 
pharmacological activities. At cellular levels, curcumin 
exhibited anti-apoptotic activity on a variety of cancer 
cell lines such as human colon cancer (17), colorectal 
(12), breast (16) and prostate (27). In certain cell culture 
systems, curcumin possesses anti-microbial, anti-fun-
gal as well as anti-viral activities. It also demonstrated 
anti-nociceptive activity in ganglion neurons, anti-para-
sitic, anti-malarial and anti-oxidant properties in blood 
plasma and platelets as well as in numerous cell lines 
(9). Meanwhile, at molecular level, curcumin is able 
to modulate the expressions of various proteins such 
as inflammatory cytokines and enzymes, transcription 
factors and gene-products that linked with cell survivals 
and proliferation (19). However, due to its poor solubili-
ty, instability and interference in several modes of assay 
in vitro, its efficacy has been improved through some 
chemical modification producing several analogues to 
maximize its antitumor effect (23). These synthetic ana-
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(MMP-9) that is related to cell migration and invasion 
as well as membrane type 1 matrix metalloproteinase 
(MT1-MMP) that is associated with the degradation of 
the matrix in invadopodia formation (10). Results from 
this study demonstrated that curcumin and its analogue, 
BHMC were able to exhibit cytotoxicity effect against 
HepG2 cells. However, BHMC exhibited lower cumula-
tive IC
50
 value for HepG2 compared to curcumin (Table 
I). These inhibitory effects were in time- and concen-
tration- dependent manner. Toxicity effects of curcumin 
and BHMC has been further confirmed via trypan blue 
assay which indicated that BHMC was more cytotoxic 
towards HepG2 compared to curcumin.
Despite being a very potent antitumor compound, com-
parative toxicology study has been demonstrated that 
curcumin and its analogues exhibit lowest toxicity in 
normal human hepatocytes, rat hepatocytes and human 
fibroblast in vitro (3). However, in this study both cur-
cumin and BHMC exerted their toxicity effect towards 
the non-cancer 3T3 based on the reduced number of 
cell viability and low IC
50
 values. Although the exact 
mechanism has not been fully elucidated, it is indeed 
necessary to evaluate and verify the toxicity effect of 
BHMC on several other normal cell lines as well as in 
vivo study (28). 
Morphologically, BHMC- and curcumin-treated HepG2 
at respected concentrations has a rounded up morphol-
ogy, detached from the surface of the flask and shrunk. 
Fig. 3 and 4 showed that BHMC had a greater cytotoxic 
effect compared to curcumin towards HepG2 based on 
the present of more cells shrinkage as well as a decrease 
in the appearance of viable cells. The treated cells were 
deformed and demonstrated morphologic hallmark of 
apoptosis such as nuclear compaction, cytoplasmic 
constriction and reduction in cell volume. They also 
demonstrated membrane blebbing, nuclear condensa-
tion and apoptotic bodies which were later being phago-
cytosed by neighboring cells such as macrophages and 
parenchymal cells. This process is important to control 
abnormal growth of cancer cells. However, our quali-
tative results of curcumin-treated HepG2 demonstrated 
less cells with apoptotic features compared to BHMC. 
Although the exact mechanism underlying BHMC’s an-
ti-proliferative effect is not been fully elucidated, this 
compound has the potential to be developed into new 
chemotherapeutic agent to combat malignancy. 
Majority of curcumin’s analogues has been reported to 
be able to exert better anti-proliferative effect on cancer 
cells compared to curcumin through induction of apop-
tosis. Some mono-carbonyl analogues not only have 
enhanced anti-tumour activities in vitro but also have 
better pharmacokinetic profiles in vivo (28). Although 
curcumin analogue of 3,30-hydroxy was able to signifi-
cantly induced apoptosis in HepG2 via ROS mediated 
pathway (15), there was no report on the effect of BHMC 
on this cell line. Mono-carbonyl curcumin analogue of 
Figure 4: Morphological changes of curcumin-treated HepG2 and 3T3 
observed under an inverted light microscope (40X magnifications). 
Cell population decreased with the increase in compound concen-
tration. Both treated cells showed the apoptotic features such as cel-
lular detached cell (dc), cell shrinkage (cs) and membrane blebbing 
(mb) and formation of apoptotic bodies (ab). Healthy cells remained 
attached (ac) to the surface of the flask.  
logues of curcumin is claimed to possess similar safety 
profile as parent compound as well as improved bio-
availability (28). 
One of the curcumin’s derivative is known as 
2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexa-
none or BHMC has been synthesized with mono cyclic 
ketone replacing the diketone moiety of curcumin (21). 
It possesses α,β-unsaturated bis-enone system which is 
important to enhance several biological effects includ-
ing anticancer as in chalcones and bis-chalcones (20). 
Numerous studies had reported the anti-nociceptive ef-
fect of BHMC on mice is triggered through inhibition of 
various inflammatory mediators (18, 25). It also demon-
strated anti-metastasis effect in vivo using mouse model 
4T1 with lower tumour burden, less mitotic cells in the 
tumour and lung metastasis upon treatment with BHMC 
(23). Meanwhile, anti-proliferative effect of BHMC was 
demonstrated in in vitro models using several can-
cer cell lines. Comparatively, BHMC has greater cyto-
toxic effect on human breast cancer cells, MCF-7 and 
MDA-MB-231 than curcumin. It inhibits the signaling 
pathway that consists of NF-kB, activator protein (AP-
1) and mitogen-activated protein kinase (MAPK). It also 
reduced the expression of matrix-metalloproteinase-9 
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GL63 also has been reported to have better effect on the 
activation of caspases-3 and -9, which play major role in 
regulating apoptosis (28). Incorporation of multiple pairs 
of methoxy groups at either end of the compound as 
well as cyclohexanone linker between the two benzene 
rings in curcumin analogue is essential to increase the 
toxicity effect against cancer cell lines (5). Although all 
these derivatives were able to induce anticancer effects 
in both in vivo and in vitro, exact molecular mechanism 
underlying these activities are still unclear (14). 
CONCLUSION
This study demonstrated that BHMC was cytotoxic 
towards HepG2 in concentration- and time-dependent 
manner compared to curcumin. This has been confirmed 
with trypan blue assay and morphological studies of 
treated cells. Although curcumin’s analogue, BHMC 
was relatively toxic towards non-cancer 3T3, several 
normal cell lines should be used to confirm the toxicity 
of BHMC. 
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